Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia

E-ISSN： 1099-1069|36|1|366-369

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 366-369

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

By Plosker G.L. Figgitt D.P.

Drugs, Vol. 63, Iss. 8, 2003-01 ,pp. : 803-843

Adis International

Access to resources Recommend Favorite

Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

By Cvetković Risto S. Perry Caroline M.

Drugs, Vol. 66, Iss. 6, 2006-01 ,pp. : 791-820

Adis International

Access to resources Recommend Favorite

Rituximab for the Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

By Hagemeister Fredrick

Drugs, Vol. 70, Iss. 3, 2010-02 ,pp. : 261-272

Adis International

Access to resources Recommend Favorite

Alvocidib [flavopiridol] may be an effective treatment for patients with refractory chronic lymphocytic leukaemia

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Management of Chronic Lymphocytic Leukaemia

By Kalil N. Cheson B.D.

Drugs & Aging, Vol. 16, Iss. 1, 2000-01 ,pp. : 9-27

Adis International

Access to resources Recommend Favorite